Johnson & Johnson expects a lucrative return from its pharmaceutical business, with plans to seek approval by 2019 for more than 10 new products, each with the potential to top $1 billion in annual sales.
Dying patients sometimes seek emergency access to experimental medicines, desperate for a last-chance treatment even if there's little proof it could help. Now drug giant Johnson & Johnson is taking an unusual ...
US health care giant Johnson & Johnson announced plans Friday to collaborate with Google on surgical robotics.
Amgen Inc., the Thousand Oaks, Calif., biotech giant, said Sunday a new study has found its cancer drug Kyprolis is far more effective in treatment of relapsed multiple myeloma than its chief rival.
Boston Scientific will pay $600 million to settle with drugmaker Johnson & Johnson over the medical device maker's $27 billion acquisition of Guidant Corp. in 2006.
Imagine being able to identify people likely to develop a particular disease—and then stop it before it starts. This isn't a science fiction tale. It's the ambitious goal of three research projects just launched by Johnson ...
There is no licensed vaccine or treatment for Ebola, which has killed more than 8,600 people in West Africa out of more than 21,700 infected since the start of 2014.
The Yale University Open Data Access (YODA) Project is announcing the first-ever broad availability of clinical trial data for medical devices and diagnostics by a company. This historic expansion of data ...
The nation's largest pharmacy benefits manager is throwing its weight into the fight over high-cost hepatitis C drugs with a coverage restriction that might ultimately lower prices and improve patient access ...
U.S. regulators on Monday strengthened their warning against use of a once-popular device for gynecologic surgery that can spread unsuspected cancer, saying its risk is only justified in a fraction of patients.
Johnson & Johnson will begin safety testing in early January on a vaccine combination that could protect people from a strain of the deadly Ebola virus.
Johnson & Johnson is buying the biopharmaceutical company Alios BioPharma Inc. for about $1.75 billion.
(HealthDay)—The largest maker of a surgical tool that has shown an increased risk of spreading undetected cancers in women has said it will withdraw its device from the market.
Two California counties have filed a lawsuit accusing five drug companies of waging a campaign of deception to boost the sales of painkillers behind the nation's prescription drug addiction problem.
Johnson & Johnson is halting sales of devices used to remove growths in the uterus following a government warning that the electronic surgical tools can inadvertently spread cancer to other parts of the body.